Genoskin

Founded in 2014 and based in Toulouse, France, Genoskin has established itself as a leader in providing human-relevant skin biology data through its patented ex vivo skin platform. The company operates a dual business model, offering direct sales of its standardized skin models (NativeSkin, HypoSkin, InflammaSkin, WoundSkin) via an e-shop and providing tailored contract research services for drug and product development. With a focus on dermatology, immunology, and drug delivery, Genoskin partners with a significant portion of the top 20 pharmaceutical companies, accelerating research in areas like inflammatory diseases, vaccine development, and cosmetic safety.

Proprietary ex vivo platform that maintains donated, full-thickness natural human skin alive and functionally intact for at least 7 days. Includes specialized models (NativeSkin, HypoSkin, InflammaSkin, WoundSkin) and primary human mast cells, preserving native skin architecture and immune components.

Genoskin competes with providers of reconstructed human skin models (e.g., MatTek, Episkin), organ-on-a-chip companies, and traditional animal testing CROs. Its key differentiator is the use of *natural*, full-thickness human skin with an intact immune system, offering superior biological complexity and human relevance compared to engineered or animal models.